20% off purchase of 3 or more products* | Learn More >>

Product listing: LIN28A (A177) Antibody, UniProt ID Q9H9Z2 #3978 to MALT1 Antibody, UniProt ID Q9UDY8 #2494

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry, Immunofluorescence (Immunocytochemistry), Western Blotting

Background: LIN28A and LIN28B are conserved, developmentally regulated RNA binding proteins that inhibit the processing and maturation of the let-7 family of miRNAs (1,2). The let-7 miRNAs have been implicated in repression of oncogenes such as Ras, Myc, and HMGA2 (3). It has recently been shown that upregulation of LIN28A and LIN28B in primary human tumors and human cancer cell lines is correlated with downregulation of let-7 miRNAs (4). LIN28 genes are reported to be involved in primordial germ cell development and germ cell malignancy (5). In addition, allelic variation in LIN28B is associated with regulating the timing of puberty in humans (6). Overexpression of LIN28A, in conjunction with Oct-4, Sox2, and Nanog, can reprogram human fibroblasts to pluripotent, ES-like cells (7).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: LIN28A and LIN28B are conserved, developmentally regulated RNA binding proteins that inhibit the processing and maturation of the let-7 family of miRNAs (1,2). The let-7 miRNAs have been implicated in repression of oncogenes such as Ras, Myc, and HMGA2 (3). It has recently been shown that upregulation of LIN28A and LIN28B in primary human tumors and human cancer cell lines is correlated with downregulation of let-7 miRNAs (4). LIN28 genes are reported to be involved in primordial germ cell development and germ cell malignancy (5). In addition, allelic variation in LIN28B is associated with regulating the timing of puberty in humans (6). Overexpression of LIN28A, in conjunction with Oct-4, Sox2, and Nanog, can reprogram human fibroblasts to pluripotent, ES-like cells (7).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: LIN28A and LIN28B are conserved, developmentally regulated RNA binding proteins that inhibit the processing and maturation of the let-7 family of miRNAs (1,2). The let-7 miRNAs have been implicated in repression of oncogenes such as Ras, Myc, and HMGA2 (3). It has recently been shown that upregulation of LIN28A and LIN28B in primary human tumors and human cancer cell lines is correlated with downregulation of let-7 miRNAs (4). LIN28 genes are reported to be involved in primordial germ cell development and germ cell malignancy (5). In addition, allelic variation in LIN28B is associated with regulating the timing of puberty in humans (6). Overexpression of LIN28A, in conjunction with Oct-4, Sox2, and Nanog, can reprogram human fibroblasts to pluripotent, ES-like cells (7).

$260
100 µl
APPLICATIONS
REACTIVITY
Mouse

Application Methods: Western Blotting

Background: LIN28A and LIN28B are conserved, developmentally regulated RNA binding proteins that inhibit the processing and maturation of the let-7 family of miRNAs (1,2). The let-7 miRNAs have been implicated in repression of oncogenes such as Ras, Myc, and HMGA2 (3). It has recently been shown that upregulation of LIN28A and LIN28B in primary human tumors and human cancer cell lines is correlated with downregulation of let-7 miRNAs (4). LIN28 genes are reported to be involved in primordial germ cell development and germ cell malignancy (5). In addition, allelic variation in LIN28B is associated with regulating the timing of puberty in humans (6). Overexpression of LIN28A, in conjunction with Oct-4, Sox2, and Nanog, can reprogram human fibroblasts to pluripotent, ES-like cells (7).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: Leucine-rich repeat and immunoglobulin domain-containing protein (LINGO-1) is a potent negative modulator of neuronal processes including neuronal survival, axonal integrity, oligodendrocyte differentiation, and myelination (1-5). LINGO-1, Nogo receptor (NgR), and p75 neurotrophin receptor (p75NTR), or TNF receptor orphan Y (TROY) form a tripartite receptor complex, which activates RhoA/ROCK signaling and is responsible for the inhibition effect of myelin- associated factors (6,7). LINGO-1 is abundantly expressed in the brain and is implicated in various neurodegenerative disorders such as Essential tremor, multiple sclerosis and Parkinson’s disease (8-11). Recently, LINGO-1 was reported to bind directly to amyloid precursor protein (APP), promoting its degradation through lysosomal proteolysis (12). This research study implicated that Lingo-1 plays a critical role in the pathophysiology of Alzheimer's disease.

$111
20 µl
$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: Lipin 1 was identified as a nuclear protein required for adipose tissue development (1). The expression of Lipin 1 is induced during adipocyte differentiation (1). The abnormal development of adipose tissues caused by mutations in the lipin 1 gene results in lipodystrophy, a condition associated with low body fat, fatty liver, hypertriglyceridemia, and insulin resistance (1). Lipin 1 plays a role in lipid metabolism in various tissues and cell types including liver, muscle, adipose tissues, and neuronal cell lines (2-4). It has dual functions at the molecular level: Lipin 1 serves as a transcriptional coactivator in liver, and a phosphatidate phosphatase in triglyceride and phospholipid biosynthesis pathways (5). Lipin 1 is regulated by mTOR, illustrating a connection between adipocyte development and nutrient-sensing pathways (6). It also mediates hepatic insulin signaling by TORC2/CRTC2 (7).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Western Blotting

Background: Liprins are a family of proteins known to function as LAR (leukocyte common antigen-related) transmembrane protein tyrosine phosphatase-interacting proteins (1). This interaction has been studied in connection to both axon guidance and mammary gland development (1,2). Liprin β1, a member of this family, is a widely expressed, multivalent cytosolic protein. Liprin β1 has been found to homodimerize at the N terminus and to heterodimerize with Liprin α1 and the metastasis-associated protein S100A4 at the C terminus (1,2). The interaction with S100A4 is believed to both inhibit its phosphorylation and to modulate complex formation with Liprin α1, resulting in a change in LAR cell adhesion properties, thus promoting cell motility and tumor metastasis (2). Liprin β1 has also been shown to have higher expression levels and to associate with KANK proteins in melanoma and to be a potential regulator of lymphatic vessel integrity (3,4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Western Blotting

Background: LIS1 is a cytoskeleton-interacting protein that contains an N-terminal dimerization domain and a C-terminal β-propeller domain that interacts with the motor domain of dynein (1-3). Research studies have shown that mutations in the LIS1 gene are involved in lissencephaly, a disease characterized by severe defects in brain development (4). LIS1 also plays a critical role in cortical migration and development in the brain (5). LIS1 activity is required for retrograde translocation of excitatory synapses in developing interneuron dendrites in a microtubule-dependent fashion (6).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: LITAF (PIG7/SIMPLE) is protein that contributes to the regulation of the inflammatory cytokine TNF-α (1-3). LITAF was identified as a transcription factor involved in LPS-induced TNF-α expression through interaction with the TNF-α promoter (1,4). The same protein, called PIG7, was independently described in a model for p53 regulation (2). A putative alternative spiced form of LITAF, named SIMPLE, encodes a protein with a unique carboxyl terminus (3). Studies on LITAF-deficient mice demonstrate that LITAF plays a significant role in the regulation of several inflammatory cytokines in response to LPS (5). The regulation of LITAF can occur through phosphorylation by p38α via the TLR pathway that leads to its nuclear translocation (5). Mutation in the LITAF/SIMPLE gene has been associated with an autosomal dominant demyelinating form of Charcot-Marie-Tooth disease (6).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: Leucine-rich immunoglobulin repeats 1 (LRIG1) is a type I transmembrane protein containing 15 leucine rich repeats and three immunoglobulin domains in the extracellular domain. Researchers characterize LRIG1 as a negative regulator of receptor tyrosine kinase signaling. In studies with ErbB family members and Met kinase, LRIG regulates signaling by increasing ubiquitination and lysosomal degradation of the receptors (1,2). Additional work indicates that LRIG1 plays a role in neurotropic signaling by negatively regulating Ret signaling (3,4). Expression profile studies demonstrate that LRIG1 is a marker in the quiescent population of stem cells in the intestine (5). Interestingly, the genetic ablation of one allele of LRIG1 in mice with an APC+/- background results in development of highly dysplastic adenomas, indicating a role for LRIG1 in tumor suppression (1). Indeed, down-regulation of LRIG1 is tentatively involved in tumor aggressiveness in several tumor types, including glioma (6), head and neck cancer (7), and cervical adenocarcinoma (8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Low density lipoprotein receptor related protein 1 ( LRP1) is a type I transmembrane receptor that mediates the endocytosis of various ligands (1). LRP1 plays important roles in lipid homeostasis, signaling transduction, embryonic development, and glucose metabolism (2-6). In addition, LRP1 regulates APP processing and facilitates the clearance of beta-amyloid (7-9). This finding makes LRP1 a potential therapeutic target for Alzheimer’s disease. LRP1 preprotein is proteolytically processed by furin to generate a 515 kDa extracellular α subunit and a membrane-anchored 85 kDa β subunit, which together form the mature receptor (10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Leucine-rich repeat containing 8 family member A (LRRC8A) belongs to the leucine-rich repeat family of proteins. It is also named SWELL1. LRRC8A forms a heteromeric complex called the volume regulated anion channel (VRAC) with other family members such as LRRC8B, LRRC8C, LRRC8D, or LRRC8E. VRAC maintains cell volume in response to extracellular or intracellular osmotic changes (1,2). The LRRC8A-containing VRAC complex senses ionic strength and is activated by hypotonic stress (3). LRRC8A is also involved in B cell development. Mutations in the LRRC8A gene causes agammaglobulinemia, which is a primary immunodeficiency characterized by severely low or absent serum antibodies and circulating B-cells (4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmarks of PD are progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem (1). Research studies have shown various genes and loci are genetically linked to PD including α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2 (2).Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. Research studies have linked at least 20 LRRK2 mutations to PD, with the G2019S mutation being the most prevalent (3). The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length that leads to progressive neurite loss and decreased neuronal survival (4). Researchers are currently testing the MLK inhibitor CEP-1347 in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD (5).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Chromatin IP, Flow Cytometry, Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: Lysine-specific demethylase 1 (LSD1; also known as AOF2 and BHC110) is a nuclear amine oxidase homolog that acts as a histone demethylase and transcription cofactor (1). Gene activation and repression is specifically regulated by the methylation state of distinct histone protein lysine residues. For example, methylation of histone H3 at Lys4 facilitates transcriptional activation by coordinating the recruitment of BPTF, a component of the NURF chromatin remodeling complex, and WDR5, a component of multiple histone methyltransferase complexes (2,3). In contrast, methylation of histone H3 at Lys9 facilitates transcriptional repression by recruiting HP1 (4,5). LSD1 is a component of the CoREST transcriptional co-repressor complex that also contains CoREST, CtBP, HDAC1 and HDAC2. As part of this complex, LSD1 demethylates mono-methyl and di-methyl histone H3 at Lys4 through a FAD-dependent oxidation reaction to facilitate neuronal-specific gene repression in non-neuronal cells (1,6,7). In contrast, LSD1 associates with androgen receptor in human prostate cells to demethylate mono-methyl and di-methyl histone H3 at Lys9 and facilitate androgen receptor-dependent transcriptional activation (8). Therefore, depending on gene context LSD1 can function as either a transcriptional co-repressor or co-activator. LSD1 activity is inhibited by the amine oxidase inhibitors pargyline, deprenyl, clorgyline and tranylcypromine (8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: LSP1 is a 52 kDa leukocyte-specific protein expressed in B cells, T cells, macrophages and neutrophils (1). The protein binds F-actin through its C-terminal actin-binding repeat and regulates cytoskeletal-related cellular movement such as polarization, chemotaxis and locomotion (2-4). LSP1 is a phospho-protein and has been identified as a major substrate of MAP kinase and PKC in lymphocytes and neutrophils (5-7). The phosphorylation is possibly related to its cytoskeletal regulatory function.

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Western Blotting

Background: Lu/BCAM (CD239) is a transmembrane cell adhesion molecule belonging to the immunoglobulin superfamily (1). The protein mediates cell adhesion by binding to basal membrane laminin α5, and cell surface integrin α4β1 (2,3). The interaction between Lu/BCAM and its ligands can be activated via phosphorylation in its cytoplasmic tail by either PKA or Akt signaling (4,5). In sickle cell disease, Lu/BCAM was reported to promote abnormal red blood cell adhesion to endothelium, and thus may contribute to vaso-occlusive crisis (6). Overexpression of Lu/BCAM has also been reported in breast cancer, skin cancer, colon cancer, and ovarian cancer (7, 8). Antibody-drug conjugates targeting Lu/BCAM on tumor cells surface has been proposed as a potential approach for cancer therapy (8).

$260
100 µl
APPLICATIONS
REACTIVITY
Mouse

Application Methods: Western Blotting

Background: Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Lyn, one of the Src family members, is predominantly expressed in hematopoietic cells (1). Two tyrosine residues have been reported to play a crucial role in the regulation of protein tyrosine kinases of the Src family. Autophosphorylation of Tyr396 (equivalent to Tyr416 of Src), located in the catalytic domain, correlates with enzyme activation. Csk-mediated phosphorylation of the carboxy-terminal Tyr507 (equivalent to Tyr527 of Src) inactivates the kinase. Tyrosine phosphorylation and activation of Lyn occurs upon association with cell surface receptors such as the B cell Ag receptor (BCR) and CD40 (2-4). Studies using knockout mice have shown that the net effect of Lyn deficiency is to render B cells hypersensitive to BCR stimulation (5-7), suggesting that the most critical role for Lyn in vivo is in the down-regulation of B cell responses. Lyn is also involved in controlling the migration and development of specific B cell populations (8).

$260
100 µl
APPLICATIONS
REACTIVITY
Mouse, Rat

Application Methods: Western Blotting

Background: Lysozymes are secreted proteins that have bacteriolytic function which are critical for mammalian innate immune function. All lysozymes function to defend host animals from microbial infection by hydrolyzing bacterial cell wall peptidoglycan (1). Conventional-type lysozymes (Lysozyme C) are one of three types of lysozymes; each family member is categorized based on amino acid sequence and biochemical properties. Lysozyme C is expressed in mammalian secretions like tears, urine, and milk, but are also expressed by phagocytes such as macrophages, neutrophils, and dendritic cells. Lysozyme C is encoded in humans by a single LYZ gene. The mouse orthologs of Lysozyme C are encoded by two genes, Lyz1 and Lyz2, which encode Lysozyme C-1 and Lysozyme C-2 (Lysozyme C-1/2). Interestingly, Lyz2 is upregulated in microglia of Alzheimer's disease mouse model brains that have been stimulated by specific forms of activity (2). Lyz1 and Lyz2 are uniquely expressed in microglia, and increased Lyz2 correlates with microglia-mediated β-amyloid (Aβ) clearance, suggesting that Lysozyme C-1/2 may directly contribute to microglial-clearance of Aβ or act as a marker for certain microglial activity states in the brain (3).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Lysyl-tRNA synthetase (LysRS) is a multifunctional protein that has both regular and mitochondrial forms. The regular form of LysRS belongs to a family of aminoacyl-tRNA synthetases (aaRSs) that catalyze amino acid attachment to its cognate tRNA. In mammalian systems, LysRS forms a multisystem complex (MSC) with several other aaRSs (1-3). In addition to its conventional function, LysRS regulates diadenosine tetraphosphate (Ap4A) production (3). Cellular and metabolic stress increases the level of Ap4A, which functions as a cellular alarm system (3-5). Following FcεRI aggregation in mast cells, MAPK/Erk kinase (MEK) phosphorylates LysRS at Ser207 (5). Serine phosphorylation of LysRS leads to the release of LysRS from MSC and its translocation into the nucleus (5), as well as increased synthesis of Ap4A (5,6). LysRS binds to microphthalmia transcription factor (MITF) and MITF repressor Hint-1. Upon binding of Ap4A, Hint-1 is released from the complex that in turn allows the transcription of MITF-responsive genes (5-7). LysRS is also involved in HIV viral assembly through incorporation into HIV-1 virions via an interaction with HIV-1 Gag (8). Research studies have shown that in the presence of mutant Cu,Zn-superoxide dismutase (SOD1), mitochondrial LysRS tends to be misfolded and degraded by proteasomal degradation, contributing to mitochondrial dysfunction in Amyotrophic Lateral Sclerosis (ALS) (9). LysRS is also secreted and has cytokine-like functions (10). LysRS was also found to be an autoantigen in autoimmune responses (11).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Western Blotting

Background: Macrophage-colony stimulating factor (M-CSF, CSF-1) receptor is an integral membrane tyrosine kinase encoded by the c-fms proto-oncogene. M-CSF receptor is expressed in monocytes (macrophages and their progenitors) and drives growth and development of this blood cell lineage. (1-3). Binding of M-CSF to its receptor induces receptor dimerization, activation, and autophosphorylation of cytoplasmic tyrosine residues used as docking sites for SH2-containing signaling proteins (4). There are at least five major tyrosine autophosphorylation sites. Tyr723 (Tyr721 in mouse) is located in the kinase insert (KI) region. Phosphorylated Tyr723 binds the p85 subunit of PI3 kinase as well as PLCγ2 (5). Phosphorylation of Tyr809 provides a docking site for Shc (5). Overactivation of this receptor can lead to a malignant phenotype in various cell systems (6). The activated M-CSF receptor has been shown to be a predictor of poor outcome in advanced epithelial ovarian carcinoma (7) and breast cancer (8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Western Blotting

Background: Histone macroH2A1 and macroH2A2 comprise a family of variant histone H2A proteins. MacroH2A1 exists as two distinct isoforms due to alternative splicing of a single gene; macroH2A1.1 levels accumulate throughout differentiation and development while macroH2A1.2 shows a constant level of expression (1). MacroH2A1 and macroH2A2 are encoded by completely distinct genes located on separate chromosomes (2,3). Both macroH2A1 and macroH2A2 proteins contain an amino-terminal histone-like region with 64% sequence identity to canonical histone H2A, in addition to a carboxy-terminal “macro” domain (1-3). MacroH2A1 and macroH2A2 are enriched in facultative heterochromatin, including inactivated X chromosomes in mammalian females and senescence-associated heterochromatin foci (2-5). Both act to repress gene transcription by inhibiting the binding of transcription factors to chromatin, the acetylation of histones by p300, and the chromatin-remodeling activities of SWI/SNF and ACF (6,7). The macro domain of macroH2A1.1 binds to ADP-ribose and functions to recruit macroH2A1.1 to activated PARP at sites of DNA damage, where it mediates chromatin rearrangements to locally regulate the DNA damage response (8). MacroH2A1.2 and macroH2A2 do not bind poly-ADP-ribose and are not recruited to sites of activated PARP (8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunofluorescence (Immunocytochemistry), Western Blotting

Background: Histone macroH2A1 and macroH2A2 comprise a family of variant histone H2A proteins. MacroH2A1 exists as two distinct isoforms due to alternative splicing of a single gene; macroH2A1.1 levels accumulate throughout differentiation and development while macroH2A1.2 shows a constant level of expression (1). MacroH2A1 and macroH2A2 are encoded by completely distinct genes located on separate chromosomes (2,3). Both macroH2A1 and macroH2A2 proteins contain an amino-terminal histone-like region with 64% sequence identity to canonical histone H2A, in addition to a carboxy-terminal “macro” domain (1-3). MacroH2A1 and macroH2A2 are enriched in facultative heterochromatin, including inactivated X chromosomes in mammalian females and senescence-associated heterochromatin foci (2-5). Both act to repress gene transcription by inhibiting the binding of transcription factors to chromatin, the acetylation of histones by p300, and the chromatin-remodeling activities of SWI/SNF and ACF (6,7). The macro domain of macroH2A1.1 binds to ADP-ribose and functions to recruit macroH2A1.1 to activated PARP at sites of DNA damage, where it mediates chromatin rearrangements to locally regulate the DNA damage response (8). MacroH2A1.2 and macroH2A2 do not bind poly-ADP-ribose and are not recruited to sites of activated PARP (8).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: Members of the Myc/Max/Mad network function as transcriptional regulators with roles in various aspects of cell behavior including proliferation, differentiation and apoptosis (1). These proteins share a common basic-helix-loop-helix leucine zipper (bHLH-ZIP) motif required for dimerization and DNA-binding. Max was originally discovered based on its ability to associate with c-Myc and found to be required for the ability of Myc to bind DNA and activate transcription (2). Subsequently, Max has been viewed as a central component of the transcriptional network, forming homodimers as well as heterodimers with other members of the Myc and Mad families (1). The association between Max and either Myc or Mad can have opposing effects on transcriptional regulation and cell behavior (1). The Mad family consists of four related proteins; Mad1, Mad2 (Mxi1), Mad3 and Mad4, and the more distantly related members of the bHLH-ZIP family, Mnt and Mga. Like Myc, the Mad proteins are tightly regulated with short half-lives. In general, Mad family members interfere with Myc-mediated processes such as proliferation, transformation and prevention of apoptosis by inhibiting transcription (3,4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: MAFB belongs to the musculoaponeurotic fibrosarcoma (MAF) family of basic leucine-zipper transcription factors (1). In mouse embryo, MAFB expression is first detected at E10.5 (2, 3). Early in development, MAFB drives differentiation of both glucagon-producing α-cells and insulin-producing β-cells in the pancreas, but later plays a more decisive role in the maturation and maintenance of functional α-cells (4, 5). Consistent with MAFB playing a critical role in mature α-cells, MAFB is enriched in α-cells within 2 weeks of birth in the pancreas (6). Glucagon and insulin secretion is tightly regulated, and imbalances in these hormones contribute to metabolic conditions. Therefore, understanding the role of MAFB in α-cell development, maintenance, and physiological function may contribute to developing deeper insights into how these cells contribute to metabolic diseases like diabetes. MAFB also regulates monocyte differentiation, indicating MAFB functions beyond the pancreas (7).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey

Application Methods: Immunoprecipitation, Western Blotting

Background: Cytosolic malic enzyme (ME1) catalyzes the conversion of malate and NADP+ to pyruvate and NADPH (1,2). NADPH is then used for fatty acid biosynthesis and lipogenesis (1,2). Cytosolic malic enzyme was shown to mediate high fat diet-induced adiposity (1). Mitochondrial malic enzyme (ME2) preferentially uses NAD+ to catalyze the conversion of malate to pyruvate with the concomitant generation of NADH (2). Recent studies have demonstrated that the tumor suppressor p53 regulates cell metabolism and proliferation by repressing the expression of both cytosolic malic enzyme and mitochondrial malic enzyme (3).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Western Blotting

Background: Malic enzymes catalyze oxidative decarboxylation of malate to pyruvate (1). The malic enzyme family in mammalian cells includes the cytosolic malic enzyme 1 (ME1) and two mitochondrial malic enzymes (ME2 and ME3) (1, 2). ME1 and ME2 are critical for tumor cell growth and their expression is repressed by tumor suppressor p53 (2). Reduced expression of ME1 and ME2 reciprocally increases the levels and activation of p53, promoting p53-mediated senescence (2). Research studies show ME3 is essential for the survival of pancreatic ductal adenocarcinoma following genomic deletion of ME2 (3). Deletion of ME3 is lethal to ME2-null cancer cells, which has been suggested to provide a potential therapeutic opportunity using collateral lethality (3, 4).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Mucosa-associated lymphoid tissue translocation gene 1 (MALT1) is a paracaspase that is a critical mediator of T-cell receptor activation of NF-κB and may contribute to the progression of MALT lymphomas (1-4). It contains two immunoglobulin-like domains, an amino-terminal death domain and a carboxy-terminal caspase-like domain. Association of MALT1 with Bcl-10 and CARD11/Carma1 leads to activation of IKK and subsequent stimulation of NF-κB, resulting in increased proliferation and inhibition of apoptosis (5,6). A common translocation in MALT B-cell non-Hodgkin lymphomas t(11;18)(q21;q21) results in the fusion of the amino terminus of API2 (c-IAP2), a member of the inhibitor of apoptosis protein family, to the carboxy terminus of MALT1 (1,2). The API2-MALT1 fusion protein likely leads to deregulation of NF-κB, contributing to increased oncogenic potential (7).